Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Pages: -
Ahead of Print: 2017-02-09

Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant

Online Supplementary Material

D. Albrecht (1), D. Ellis (2), D. M. Canafax (3), D. Combs (4), P. Druzgala (1), P. G. Milner (1), M. G. Midei (5)

(1) Armetheon, Milpitas, California, USA; (2) DURECT Corp, Cupertino, California, USA; (3) Theravance Biopharma, San Francisco, California, USA; (4) Combs Consulting, San Francisco, California, USA; (5) Armetheon, Inc, Monkton, Maryland, USA


Pharmacokinetics, pharmacodynamics, warfarin, VKA, tecarfarin


Tecarfarin is a vitamin K antagonist (VKA) with reduced propensity for drug interactions. To evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and safety of tecarfarin, we performed single ascending dose (SAD) (n=66), multiple ascending dose (MAD) (n=43), and tecarfarin versus warfarin (n=28) studies in human volunteers. In the SAD, tecarfarin was administered to 5 of 6 subjects (1 received placebo) in each of 11 cohorts. AUC0-∞ exhibited linearity and dose proportionality. Elimination T1/2 ranged from 87–136 hours (h) across all doses. In the MAD, tecarfarin was administered to 5 of 6 volunteers in each of 7 cohorts. The starting dose was continued until the subject’s INR reached the target range (TR) of 1.7 to 2.0. Dosing was down-titrated if the TR was achieved. Elimination T1/2 ranged from 107–140 h. Doses <10 mg had insignificant effect on INR. Higher doses raised INRs and required down-titration to maintain the TR. Steady state INR dosing was 10–20 mg. INR declined promptly after discontinuation. In the comparative study, subjects received tecarfarin or warfarin and dose titrated to a TR of 1.5–2.0. Mean dose after TR was achieved was 13.9 mg (range 10.0–25.5 mg) for tecarfarin and 5.3 mg (range 2.5–9.0 mg) for warfarin. At similar INR levels, the concentration of coagulation factors II, VII, IX, and X were similar for tecarfarin and warfarin. Tecarfarin was tolerated well without serious adverse events in all three studies.

You may also be interested in...

Markus Hinder1 , Annke Frick 1 , Ronald Rosenburg 1 , Galina Hesse1 , Marie-Laure Ozoux2 , Volker Laux1 , Herman Scholtz 3 , Alexander Gebauer1 , Anne Paccaly

Thromb Haemost 2006 95 2: 224-228

The EmbraceAC Trial

Online Supplementary Material

R. P. Whitlock (1), C. B. Fordyce (2), M. G. Midei (3), D. Ellis (4), D. Garcia (5), J. I. Weitz (6), D. M. Canafax (7), D. Albrecht (3), P. G. Milner (3)

Thromb Haemost 2016 116 2: 241-250


G. Hefner (1), C. Hiemke (2)

Die Psychiatrie 2014 11 4: 234-244